BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
Phase 3
Completed
- Conditions
- Myopia, Pathological
- Interventions
- Biological: VEGF Trap-Eye (BAY86-5321)Procedure: No Drug
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 122
- Registration Number
- NCT01249664
GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 539
- Registration Number
- NCT01248481
Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT01235455
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 537
- Registration Number
- NCT01234337
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
Completed
- Conditions
- Relapsing Remitting MS (RRMS)Secondary Progressive MS (SPMS)
- Interventions
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2012-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1077
- Registration Number
- NCT01233245
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Phase 3
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: rFVIII (BAY81-8973) on demandBiological: rFVIII (BAY81-8973) prophylaxis low-doseBiological: rFVIII (BAY81-8973) prophylaxis high-dose
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT01233258
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ZK245186Drug: Placebo (vehicle without active ingredient)
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 263
- Registration Number
- NCT01228513
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension, Essential
- Interventions
- Drug: Nifedipine GITS (Adalat LA, BAYA1040)Drug: Candesartan (Atacand)Drug: Nifedipine-candesartan FDC (BAY 98-7106)
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 49
- Registration Number
- NCT01227603
Xirtam H Combination In the Treatment of Hypertension Evaluation Study.
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8704
- Registration Number
- NCT01219556
GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9364
- Registration Number
- NCT01219582
© Copyright 2025. All Rights Reserved by MedPath